Understanding the underlying mechanism behind of mTOR control of glutaminase C activity and identification and characterization of glutaminase C post-translational modifications by Ascenção, Carolline Fernanda Rodrigues, 1989-


Agência(s) de fomento e nº(s) de processo(s): FAPESP, 2013/23510-4; CNPq,
140545/2014-0
ORCID:  https://orcid.org/0000-0002-0882-7390
Ficha catalográfica
Universidade Estadual de Campinas
Biblioteca do Instituto de Biologia
Mara Janaina de Oliveira - CRB 8/6972
    
  Ascenção, Carolline Fernanda Rodrigues, 1989-  
 As22e AscEstudo do mecanismo de ação da via da mTOR sobre a atividade da
enzima glutaminase C e identificação e caracterização de modificações pós-
traducionais nesta enzima / Carolline Fernanda Rodrigues Ascenção. –
Campinas, SP : [s.n.], 2018.
 
   
  AscOrientador: Sandra Martha Gomes Dias.
  AscTese (doutorado) – Universidade Estadual de Campinas, Instituto de
Biologia.
 
    
  Asc1. Metabolismo. 2. Câncer. 3. Serina-treonina quinases TOR. 4.
Fosforilação. I. Dias, Sandra Martha Gomes. II. Universidade Estadual de
Campinas. Instituto de Biologia. III. Título.
 
Informações para Biblioteca Digital
Título em outro idioma: Understanding the underlying mechanism behind of mTOR control
of glutaminase C activity and identification and characterization of glutaminase C post-
translational modifications
Palavras-chave em inglês:
Metabolism
Cancer
TOR serine threonine kinases
Phosphorylation
Área de concentração: Genética Animal e Evolução
Titulação: Doutora em Genética e Biologia Molecular
Banca examinadora:
Sandra Martha Gomes Dias [Orientador]
Juliana Helena Costa Smetana
Jörg Kobarg
Ana Karina de Oliveira
Talita Miguel Marin
Data de defesa: 20-02-2018
Programa de Pós-Graduação: Genética e Biologia Molecular

















































53 
 
 
  
Tabela 1. Peptídeos de GAC identificados via LC-MS/MS a partir da amostra de GAC-V5 imunoprecipitada. 
IP Proteína 
identificada 
Peptídeo identificado Massa Carga 
Anti-V5 (GAC-
V5) 
Glutaminase kidney 
isoforma, 
mitochondrial 
 
O94925 
ESGDRNFAIGYYLK 1631,7944 +2,+3 
AQPLVTLCR 1056,575 +2 
CVQSNIVLLTQAFR 1647,8767 +3 
CVQSNIVLLTQAFRR 1803,9778 +3 
DGPGETDAFGNSEGK 1479,6114 +2 
DGPGETDAFGNSEGKELVASGENK 2407,0775 +3 
DGPGETDAFGNSEGKELVASGENKIK 2648,2566 +3,+4 
ECMDMLR 953,37689 +2 
ELVASGENK 945,47673 +2 
ELVASGENKIK 1186,6558 +2,+3 
ESGDRNFAIGYYLK 1631,7944 +2,+3 
FDYVMQFLNK 1303,6271 +2 
FSPDLWGVSVCTVDGQR 1921,8992 +2,+3 
FVIPDFMSFTSHIDELYESAK 2475,1668 +3 
FVIPDFMSFTSHIDELYESAKK 2603,2618 +4 
GIHFCHDLVSLCNFHNYDNLR 2630,1907 +3, +4 
GLSSSPSEILQELGK 1543,8094 +2 
GSTHPQPGVSPPAAPAAPGPK 1919,9854 +2,+3,$ 
GSTHPQPGVSPPAAPAAPGPKDGPGETDAFGNSEGK 3381,5862 +4 
GSTHPQPGVSPPAAPAAPGPKDGPGETDAFGNSEGKELVASGENK 4309,0523 +5 
HSFGPLDYESLQQELALK 2074,0371 +3 
HSFGPLDYESLQQELALKETVWK 2717,3701 +3,+4 
HSFGPLDYESLQQELALKETVWKK 2845,465 +4 
HSTGDTKVPFCLQSCVKPLK 2301,161 +3,+4,+5 
KCVQSNIVLLTQAFR 1775,9716 +2,+3 
KFVIPDFMSFTSHIDELYESAK 2603,2618 +3,+4 
KFVIPDFMSFTSHIDELYESAKK 2731,3567 +4 
KVSPESNEDISTTVVYR 1922,9585 +2,+3 
LFLNEDDKPHNPMVNAGAIVVTSLIK 2834,5001 +3,+4,+5 
LKECMDMLR 1194,5559 +2,+3 
LTLQTTSDGVMLDK 1520,7756 +2 
LTLQTTSDGVMLDKDLFK 2024,05 +2,+3 
LTLQTTSDGVMLDKDLFKK 2152,145 +3,+4 
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IP Proteína 
identificada 
Peptídeo identificado Massa Carga 
MAGNEYVGFSNATFQSER 2006,8792 +2,+3 
MESLGEK 792,36875 +2 
NFAIGYYLK 1087,5702 +2 
PIPNPLLGLDST 1235,6762 +2 
QGVNNAEKFDYVMQFLNK 2144,0361 +3 
RAQPLVTLCR 1212,6761 +3 
SPAGVSATLR 957,52434 +2 
VADYIPQLAK 1116,6179 +2 
VLSPEAVR 869,49707 +2 
VPFCLQSCVKPLK 1574,8313 +2, +3 
VSPESNEDISTTVVYR 1794,8636 +2,+3 
YAIAVNDLGTEYVHR 1719,858 +2, +3 
YVGKEPSGLR 1104,5928 +2,+3 
YVGKEPSGLRFNK 1493,7991 +3 
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Tabela 3. Peptídeos de parceiros de GAC identificados via LC-MS/MS a partir da amostra de GAC-V5 imunoprecipitada em células MDA-MB 436 e BT-549, tratadas 
com veículo ou rapamicina. 
 
 MDA-MB 436  
  Parceiros exclusivos das amostras tratadas com veículo  
IP Proteína identificada ID Uniprot Peptídeo identificado Massa Carga 
Número de 
replicatas 
biológicas 
Anti-V5 
(GAC-V5) 
Argininosuccinato sintetase P00966 
GQVYILGR 904,51305 +2  
2 NDLMEYAK 982,44298 +2 NQAPPGLYTK 1087,5662 +2 
Fator de elongação 2 P13639 
ETVSEESNVLCLSK 1593,7556 +2  
2 GPLMMYISK 1038,5242 +2 VNFTVDQIR 1090,5771 +2 
Fator de elongação 1γ P26641 VLSAPPHFHFGQTNR 1706,8641 +4 2 
Fator de elongação 1δ E9PRY8 
ATNFLAHEK 1029,5243 +2 
3 IASLEVENQSLR 1357,7201 +2 
SLAGSSGPGASSGTSGDHGELVVR 2184,0407 +3 
Ribonucleoproteína nuclear heterogênea H G8JLB6 HTGPNSPDTANDGFVR 1683,7601 +3 2 THYDPPR 884,41407 +2 
Isocitrato desidrogenase mitocondrial, 
subunidade γ P51553 
VATVAGSAAK 873,49198 +2 2 HKDIDILIVR 1220,7241 +3 
Proteína SEC 13 P55735 FASGGCDNLIK 1180,5547 +2 2 
Fator de transporte nuclear 2 P61970 GDKPIWEQIGSSFIQHYYQLFDNDR 3055,4464 +3 2 
Chromobox 3 Q13185 KVEEAEPEEFVVEK 1660,8196 +3 3 
  Parceiro exclusivo das amostras tratadas com rapamicina  
IP Proteína identificada ID Uniprot Peptídeo identificado Massa Carga 
Número de 
replicatas 
biológicas 
Anti-V5 
(GAC-V5) Proteína PURH P31939 TLHPAVHAGILAR 1354,7834 +4 2 
  Parceiros comuns a amostras tratadas com veículo ou com rapamicina  
IP Proteína identificada ID Uniprot Peptídeo identificado Massa Carga 
Número de 
replicatas 
biológicas 
Anti-V5 
(GAC-V5) 
Tiol redutase lisossomal induzível por 
interferon γ P13284 GMQLMHANAQR 1255,5914 +3 2 
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Desoxipusina sintase A0A087WZK0 HSSTLPPESTQVR 1437,7212 +3 3 KLEPLSQDEDQHADLTQSR 2209,0611 +3,+4 
   
   
  
BT-549 
 
  Parceiros exclusivos das amostras tratadas com veículo  
IP Proteína identificada ID Uniprot Peptídeo identificado Massa Carga 
Número de 
replicatas 
biológicas 
Anti-V5 
(GAC-V5) 
Fator de elongação 1δ E9PRY8 SLAGSSGPGASSGTSGDHGELVVR 2184,0407 +3 2 
Glutationa S-transferase subunidade P P09211 
ALPGQLKPFETLLSQNQGGK 2125,1532 +3 
2 ASCLYGQLPK 1135,5696 +2 
TLGLYGKDQQEAALVDMVNDGVEDLR 750,42759 +2 
  Parceiro exclusivo das amostras tratadas com rapamicina  
IP Proteína identificada ID Uniprot Peptídeo identificado Massa Carga 
Número de 
replicatas 
biológicas 
Anti-V5 
(GAC-V5) Glutationa S-transferase subunidade Mu1 P09488 
KYTMGDAPDYDR 1430,6136 +3 
2 
LGLDFPNLPYLIDGAHK 1881,9989 +3 
GLAHAIR 736,43441 +2 
HNLCGETEEEK 1344,5616 +2 
HNLCGETEEEKIR 1613,7468 +3 
KHNLCGETEEEK 1472,6566 +3,+4 
KYTMGDAPDYDR 1430,6136 +3 
KYTMGDAPDYDR 1430,6136 +3 
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Abstract 
The GLS gene generates the phosphate-activated glutaminase C (GAC) isoform by alternative 
splicing. Compared to the other GLS isoform kidney-type glutaminase (KGA), GAC is more 
active and potentially of particular importance for cancer cell growth. Little is known about the 
post-translational modifications that regulate GAC function. Here, we identified by mass 
spectrometry a phosphorylated serine 95 located at the GLS N-terminal domain, a domain 
shared by both isoforms. A GAC phosphomimetic mutant (S95D) ectopically expressed in 
breast cancer cells presented a decreased enzymatic activity and its expression impacted the 
utamine uptake, glutamate release and intracellular glutamate levels (compared to wild-
type GAC) without changing the GAC sub-cellular localization. Interestingly, cells expressing 
the GAC.S95D mutant presented decreased proliferation, migration and vimentin, an 
epithelial-to-mesenchymal transition regulator, protein level. These results reveal that GAC is 
post-translationally regulated by phosphorylation, which affects cellular glutamine metabolism 
and glutaminase-related cell phenotype. 
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1. Introduction 
-
ketoglutarate, an important anaplerotic source of the tricarboxylic acid cycle (TCA) in rapidly 
growing cells [1]. The glutamine skeleton also contributes to anabolic pathways as a nitrogen 
donor and to cellular redox balance since, in the form of its product glutamate, it contributes to 
glutathione synthesis [2]. Most of the cancers cells depend on glutamine metabolism because 
of its role as a building block in biosynthetic pathways, redox homeostasis, as an energy source 
[3], and for the recently discovered role of glutamine- -ketoglutarate in  the allosteric 
activation of histone demethylases and epigenetic regulation [4]. 
In cells, glutaminases are regulated by several signaling pathways such as c-MYC, 
mTOR, Rho GTPases, c-Jun  and ERK [5,6], all of which have implications for cell growth 
and are frequently altered in cancer. While mTOR, c-MYC and c-Jun affect glutaminase at 
transcriptional and post-transcriptional levels [5,6], the RhoC-NF-
positively impacts GAC enzymatic activity, likely through phosphorylation, which however 
requires further clarification [7]. In addition to this, it was demonstrated that cellular KGA 
activity is stimulated by EGF, and that KGA associates with all three kinase components of the 
Raf-1/Mek2/Erk signaling module [8]; nevertheless, none of these studies described the 
phosphorylation sites. 
Several works have described glutaminases post-translational modifications such as 
phosphorylation [9 15], succinylation [16,17], ubiquitinylation [18,19], and acetylation 
[17,20] sites. Of these, few studies using recombinant enzymes and mutations mimicking 
acetylation have provided information on how the modifications affect protein activity [21] 
and cancer cellular phenotype [22].  None of the phosphorylation sites described in GLS, 
mainly through mass spectrometry, were fully characterized regarding enzyme activity and 
impact on cell behavior.  
In this work, by using mass spectrometry, we identified an N-terminal phosphorylation 
site on the serine 95 of GAC in breast cancer cells. GAC phosphomimetic S95D presented 
decreased glutaminase activity (comparable to the wild-type protein, WT) without changing its 
mitochondrial localization. Coherently, cells expressing GAC S95D mutant presented 
decreased proliferation, migration and protein levels of the epithelium-to-mesenchymal 
transition (EMT) marker vimentin. In summary, our results shed new light on GAC post-
translational regulation in breast cancer cells.
2. Material and Methods 
2.1 Cell culture 
MDA-MB-231 (ATCC HTB-26), BT549 (ATCC HTB-122) and MDA-M 436 (ATCC HTB-
130) were purchase from American Type Culture Collection (ATCC) in March of 2014 and 
cultivated in RPMI 1640 media (Sigma) supplemented with 10% fetal bovine serum (Vitrocell) 
at 37°C in a 5% CO2 humidified incubator. MDA- MB 231 cells were used from passages 40 
to 64, BT549 from passages 60 to 88 and MDA-MB 436 from passages 40 to 55. 
2.2 Antibodies, plasmids and reagents 
The primary antibodies vinculin (Abcam ab18058), GAC (Rhea Biotechnology), vimentin 
(Santa Cruz sc-6260) and V5 (Life Technologies 46-1157) were used in the 
immunofluorescence and western blot studies. pQC mKorange IX was a gift from Connie 
Cepko (Addgene plasmid # 37344) and modified in our lab by replacing the mKO gene with 
GAC-V5. GAC-V5 was extracted from the construct pcDNA3.1/V5-His-hGAC, a kind gift 
from Dr. Richard Cerione lab (Cornell University, Ithaca, NY). The vector pQC mKorange IX 
originally contained an IRES (Internal Ribosome Entry Site) sequence, downstream of which 
was inserted the neomycin phosphotransferase (neo) gene. The neo gene, which confers 
resistance to neomycin, was extracted from pQCXI Neo DsRed-LC3-GFP, a gift from David 
Sabatini (Addgene plasmid #31183). In this construct, named pQC-MCS-IRES-G418, both 
target and neo genes are expressed under the same promoter (CMV). The mutation S95D was
performed with the QuikChange II site-directed mutagenesis kit following the manufacturer's 
instructions. Mock construct was obtained by simply removing mKO gene from the vector. 
MDA-MB 231 (passage 40) and BT549 (passage 60) were transduced with empty pQC_Mock 
or pQC_GAC-V5 or pQC_GAC.S95D-V5, selected and maintained with 200 µg/mL G418 
(Sigma). pcDNA3.1 FLIPE-600n was a gift from Wolf Frommer (Addgene plasmid #13541). 
Transient transfections were performed using polyethylenimine (PEI) 40 kDa (Sigma-Aldrich) 
at a 2:1 ratio of PEI (µg): DNA (µg) in saline solution. 
2.3 Western blot 
Cells were washed twice with cold phosphate-buffered saline (PBS) and lysed in lysis buffer 
(10 mM EDTA pH 8.0, 100 mM Tris-HCl pH 7.4, 150 mM NaCl, 10 mM sodium 
pyrophosphate, 100 mM NaF, 2 mM PMSF, 10 mM Na3VO4, 2 µg/mL aprotinin, 10 µM 
leupeptin, 1 µM pepstatin, 1% Triton X-100). Protein lysates were resolved on 10% 
polyacrylamide SDS gels and transferred onto PVDF membranes using semidry blotting using 
WypAll X60 (Kimberly Clark) filter pads and alcohol-free buffer conditions. Membranes were 
incubated with the indicated primary antibodies, washed, and probed with HRP-conjugated 
secondary antibodies for 1 hour at room temperature. Band detection was carried out with 
SuperSignal West Pico Chemiluminescent Substrate (Pierce) followed by autoradiography film 
exposure. 
2.4 Immunofluorescence 
For GAC sub-cellular location, cells were seeded in a 96-well Cell Carrier plate (Perkin Elmer) 
and allowed to attach for 24 hours at 37°C in a humidified 5% CO2 incubator. Before fixation, 
cells were incubated with 500 nM MitoTracker Deep Red (Life Technologies) for 1 h in RPMI 
complete medium. Cells were fixed in 4% paraformaldehyde/PBS for 30 min at room 
temperature, and permeabilized in 0.2% Triton X-100/PBS, blocked with 1% goat serum, 0.1% 
Triton X-100, and 20 mM glycine in PBS, and incubated with 1:2000 anti-V5 (Life 
Technologies) mouse antibody or 1:800 anti-GAC rabbit antibody (Rhea Biotechnology). For 
EMT studies, cells were fixed in 4% paraformaldehyde/PBS for 30 min at room temperature, 
permeabilized in 0.2%Triton X-100 in PBS for 5 min, then blocked with 1% goat serum, 0.1% 
Triton X-100, 20 mM glycine in PBS and incubated with 1:1000 anti-vimentin (Santa Cruz) 
antibody diluted in working solution (0.2% goat serum, 0.02% Triton X-100, 10 mM glycine 
in PBS). All primary antibodies were incubated separately for 16 hours at 4°C. Goat secondary 
anti-mouse Alexa 488 (Life Technologies) diluted 1:500 in working solution was used to detect 
GAC-V5 or vimentin, and goat secondary anti-rabbit Alexa 546 (Life Technologies) diluted 
1:500 in working solution was used to detect GAC. All secondary antibodies were incubated 
separately for 3 hours at room temperature. Nuclei were stained with 2.5 g/mL DAPI for 10 
minutes at room temperature. All data were collected using the fluorescence microscope 
Operetta High-Content Imaging System (Perkin-Elmer) and analyzed with the software 
Columbus Image Data Storage and Analysis System (Perkin-Elmer). 
2.5 Immunoprecipitation  
In brief, cell lysates containing 1 mg of total protein were incubated with anti-V5 antibody 
(Life Technologies) that was previously crosslinked (5 mg DMA in 1 mL PBS/1h 300 µL 
beads) with protein A Magbeads (Genscript). Immunoprecipitated proteins captured with 
protein A conjugated to anti-V5 (1 mg soluble protein: 40 µL beads crosslinked to 2 µg 
antibody) were washed 5 times with PBS and eluted using 4 µg of V5 peptide (Sigma). The 
samples were then boiled in 4x SDS sample buffer [23] for western blot analysis or submitted 
to mass spectrometry sample preparation. Three independent experiments were performed. 
2.6 Nanoflow Liquid chromatography tandem coupled with mass 
spectrometry (LC-MS/MS) data collection 
Briefly, the eluted GAC-V5 proteins were reduced (5 mM dithiothreitol, 25 min at 56°C), 
alkylated (14 mM iodoacetamide, 30 min at room temperature in the dark) and digested with 
trypsin (Promega). The peptides were purified on C18 StageTips [24], dried down in a vacuum 
concentrator and reconstituted in 10 µL of 0.1% formic acid. An aliquot containing 1 µL was 
analyzed on a LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific) connected to 
LC-MS/MS by an EASY-nLC system (Proxeon Biosystem) through a Proxeon 
nanoelectrospray ion source as described by Aragão and colleagues [25]. Briefly, the peptides 
were separated by a 2-30% acetonitrile gradient in 0.1% formic acid using an analytical column 
PicoFrit Column (20 cm × ID75 m, 5 m particle size) (New Objective) at a flow of 
300 nL/min over 30 min. All instrument methods for the LTQ Orbitrap Velos were set up in 
the data dependent acquisition mode. Full-scan MS spectra (m/z 300 1,600) were acquired in 
the Orbitrap analyzer after accumulation to a target value of 1e6. The resolution in the Orbitrap 
system was set to r
sequentially isolated to a target value of 50,000 and fragmented in higher-energy collisional 
dissociation with 40% normalized collision energy. The Orbitrap resolution was set to r = 7,500 
for MS/MS. Three independent biological samples were analyzed. 
2.7 Raw LC-MS/MS data analysis 
Protein and phosphosite identification were performed with MaxQuant v.1.3.0.3 [26] against 
the Human_Uniprot_release_07012015 containing CarolGLS_TAG_17092015_2 (released 
January 7th, 2015, 89.650 sequences, 35.610,298 residues; concatenated with GAC 
recombinant protein sequence) using the Andromeda search engine. Carbamidomethylation 
was set as fixed modification, and N-terminal acetylation, methionine oxidation, 
phosphorylation of serine, threonine and tyrosine as variable modifications. The search 
parameters were set to a maximum of 2 trypsin missed cleavages and a tolerance of 6 ppm for 
precursor ions and 20 ppm for fragment ions were set for protein identification. Phosphosites 
and phosphoprotein identifications were filtered for a maximum of 1% false discovery rate at 
peptide and protein levels, using reverse target-decoy database strategy with reverse peptide 
sequences as decoy entries. Using Perseus v.1.2.7.4 software [26], the identified phosphosites 
were filtered by  a 0.75 minimum localization probability, and reverse and contaminant entries 
were excluded from further analysis. Matching between runs were set and applied with a 2-min 
window and minimum ratio count of 1. The mass spectrometry proteomics data have been 
deposited to the ProteomeXchange Consortium via the PRIDE [27] partner repository with the 
dataset identifier code PXD008338.
2.8 Intracellular glutamate measurements 
The intracellular glutamate measurements were made as described by Okumoto and colleagues 
[28]. 
2.9 Quantitative PCR 
µM final concentration of random hexamers and (dT)18 mixture (7:5) following the 
MasterMix (Applied Biosystems) as instructed by the manufacturer. Samples were run on the 
Applied Biosystems 7500 real-time PCR system and analyzed following the 2- CT method. 
The following primers were used: rRNA18S (ATTCCGATAACGAACGAGAC and 
TCACAGACCTGTTATTGCTC), GAC (GATCAAAGGCATTCCTTTGG and 
TACTACAGTTGTAGAGATGTCC) and V5 (AGAATGGAAAGTCTGGGAGAGAAA and 
CCGAGGAGAGGGTTAGGGATA). 
2.10 Glutamine consumption and glutamate release  
The assay was modified from a protocol previously published [29]. Forty thousand cells were 
plated in 96-well plates, and after 12 hours the media was replaced with 40 µL of phenol red-
free RPMI supplemented with 5 mM glucose and 2 mM glutamine. Cells were then left to 
consume for 6 hours. Ten microliters of media were mixed with 180 µL of 50 mM Tris-acetate 
pH 8.6, 2 mM NAD+ and 50 mM K2HPO4 solution, and the background absorption was 
measured at 340 nm. To measure glutamate concentration, 0.3 U of glutamate dehydrogenase 
in 10 µL of 50 mM Tris-acetate pH 8.6 were added to each reaction, and after 1 hour of 
incubation at room temperature, the absorbance at 340 nm was read. To measure glutamine 
concentration, 12 pmol of recombinant glutaminase C (purified as previously published [30]) 
in 10 µL of 50 mM Tris-acetate pH 8.6 was added to the reaction and incubated for 1 hour at 
room temperature, followed by absorbance at 340 nm measurement. All the readings were 
performed on the EnSpire (Perkin Elmer) plate reader. After background subtraction, the 
concentration was defined based on a standard curve. 
2.11 Mitosox measurements 
Seven thousand cells were seeded in a 96 wells plate and left to adhere 24h at 37°C and 5% 
CO2. The media was removed, and cells incubated with 5 µM of Mitosox Red probe (Life 
Technologies) and 1 µg/mL Hoescht (Life Technologies) in HBSS buffer during 20 min at 
37°C and 5% CO2. Cells were then washed twice using PBS and Mitosox flouescence was 
captured using the fluorescence microscope Operetta (Perkin-Elmer) and analyzed with the 
software Columbus Image Data Storage and Analysis System (Perkin-Elmer).  
2.12 Glutaminase activity assay  
The glutaminase activity assay was performed as described by Redis and colleagues [31] using 
10 µg of whole cell lysate, 2 mM L-glutamine and 20 mM K2HPO4 pH 8.0. For IP-V5 eluted 
samples, 5 µL of the eluted GAC-V5 were used in the mix reaction in the same conditions as 
described above. 
2.13 Proliferation assays 
The proliferation assay was performed as described by Ferreira and colleagues [22]. 
2.14 Migration 
The wound-healing assay was adapted from previously published protocols [32]. Briefly, 24h 
before cell seeding, a collagen-coated 96 wells plate was prepared using collagen I from rat 
tail, 0.3 mg/mL solution in acetic acid 20 mM. The plate was incubated in a 37°C incubator 
with 5% CO2. Using the coated plate, 40 x 103 MDA-MB 231 cells were seeded to cover the 
bottom of the plate. After 24h at 37°C and 5% CO2, the cell medium was replaced by a serum-
free RPMI medium for 24h. The medium was then removed, and scratched using a tip. Cells 
were washed using serum-free RPMI and incubated with RPMI (buffered in Hepes, pH 7.4) 
and 20% FBS. Cells were incubated in the microscope Operetta (Perkin-Elmer) at 37°C where 
bright field images were taken every 3 hours during 24h.  The scratch area reduction was 
measured using Fiji ImageJ software. 
3. Results 
3.1  is phosphorylated 
To identify the GAC phosphorylation sites, the enzyme fused to an immunogenic V5 tag was 
ectopically expressed in the breast cancer cell lines MDA-MB 436 and BT549, then 
immunoprecipitated. After GAC elution by competition with the V5 peptide (Figure 1A for 
BT549; Supplementary Figure S1A for MDA-MB-436), the protein was digested with trypsin 
and analyzed by liquid chromatography tandem-mass spectrometry (LC-MS/MS). A 
phosphopeptide containing pS95 (GSTHPQPGVpSPPAAPAAPGPK, m/z 667.65, +3) from 
GAC-V5 immunoprecipitated was identified in both breast cancer cell lines (Tables S1 and 
S2), and the corresponding mass spectrum manually validated (Figure 1B, for BT549; Figure 
S1B for MDA-MB 436).  
3.2 The phosphomimetic mutant S95D presented decreased glutaminase 
activity in breast cancer cells compared to the WT protein 
The WT and S95D mutant GAC-V5 (herein referred as GAC.WT and GAC.S95D) were stably 
expressed in the breast cancer cell lines MDA-MB 231 and BT549 (Figure 2A and Figure S2) 
and evaluated for glutaminase cell location and activity. Due to MDA-MB 436 low 
transduction rates, it was not possible to produce cells stably expressing GAC. GAC.WT and 
GAC.S95D were located in the mitochondria of both MDA-MB 231 and BT549, as revealed 
by the V5 immunofluorescence signal co-localization with the mitochondrial fluorescent 
probe, Mitotracker Deep Red (Figure 2B). Importantly, MDA-MB 231 and BT549 cells pool 
presented equal GAC.WT and GAC.S95D protein levels as shown by densitometry of western 
blot anti-V5 bands (Figure 2A) and immunofluorescence signal (Figure 2C). BT549 and MDA-
MB 231 cells expressing GAC.S95D presented 17% and 25% less glutaminase activity, 
respectively, than the same cells expressing GAC.WT (Figure 2D). Similarly, 
immunoprecipitated GAC.S95D transiently expressed in BT549, MDA-MB 231 and MDA-
MB 436 (Figure 2E) was 14% - 49% less active than immunoprecipitated GAC.WT (Figure 
2F), while equal levels of protein were analyzed as revealed by band densitometry. Compared 
to GAC.WT-expressing MDA-MB 231 cells, GAC.S95D-expressing cells (Figure 2G) 
presented a reduction on glutamine uptake and glutamate release, while GAC.S95D-expressing 
BT549 cells had decrease glutamate intracellular levels (Figure 2H). Glutaminase is important 
to cell redox homeostasis through glutamate production, which makes glutathione and can be 
further metabolized in the glutaminolysis pathway to form NADPH [33,34]. As expected, cells 
expressing GAC.WT had decreased superoxide levels as measured with the Mitosox probe; 
however, although the GAC.S95D mutant decreased glutaminase activity as described above, 
its cellular expression did not influence mitochondria superoxide levels (Figure S3).  
3.3 GAC.S95D mutant decreased cell proliferation, migration and vimentin 
levels 
Glutaminase increases tumor proliferation and invasion [35,36]. GAC.WT and GAC.S95D 
ectopic expression in MDA-MB-231 increased cell proliferation compared to mock cells, 
consistent with glutaminase being important for cell growth (Figure 3A). Although both 
GAC.WT and GAC.S95D contributed to increasing cell proliferation compared to mock cells, 
GAC.S95D contributed 13% less at the last measured point, 96 hours (compared to GAC.WT 
. In comparison to mock cells, GAC.WT ectopic expression 
increased MDA-MB-231 cell migration in a wound-healing assay, while GAC.S95D mutant 
did not affect this parameter (Figure 3B). The EMT process increases cell motility and is related 
to cancer invasion and metastasis [37]. During EMT, vimentin expression levels increase [38] 
and it is related to cytoskeleton rearrangement [39]. Consistent with increased cell migration, 
protein level as 
evaluated by western blot (Figure 3C) and mean vimentin-immunostaining intensity (Figures 
3D and 3E); GAC.S95D ectopic expression counter-acted this effect (Figures 3C, 3D and 3E). 
These data suggest that GAC phosphorylation on serine 95 affects glutaminase activity, cell 
proliferation and motility. 
4. Discussion 
Glutaminase phosphorylation has been described by mass spectrometry in the residues 
S95 [9], T112 [9], S118 [11], Y249 [9,40], T302 [9], Y304 [40], Y357 [9], Y370 [9], Y393 
[9], Y394 [9] and S449 [9,14] of human protein, and in S242 [12], T347 [12], S348 [12] and 
S657 [15,41] of mouse protein. However, the functional effect of these protein modifications 
(and consequently their functional impact in cells) is poorly understood. 
Tsai and colleagues identified S95 phosphorylation as a possible mitogen-activated 
protein kinase (MAPK) site [9]. In this work, the entire cell lysate previously treated with 
phosphatase was trypsin-digested and incubated with cyclin-dependent kinase 2 (CDK2), 
MAPK (ERK2 specifically) or epidermal growth factor receptor (EGFR) and evaluated by 
mass spectrometry. Phosphorylation in S95 was detected only in MAPK-treated samples, 
suggesting that glutaminase is a substrate of this kinase. Additionally, it was also revealed that 
the Raf-Mek-ERK signaling pathway stimulated KGA activity in a EGF-dependent manner 
[8]. The S95 residue in the glutaminase is present within a sequence (PGVSP) that resembles 
the canonical phosphorylation site (PXS/TP) for ERK [42]. Since ERK 2 has already been 
described as a kinase of the mitochondrial protein, BCL-2 [43], it is likely that ERK may be 
the glutaminase  kinase. However, whether ERK is indeed the glutaminase  kinase and 
whether it phosphorylates the enzyme in the mitochondria or in the cytoplasm remains unclear. 
We discovered that serine 95 phosphorylation at the conserved glutaminase N-terminal 
domain [44] inhibits glutaminase activity in breast cancer cells. Ectopic GAC.WT and 
GAC.S95D, were all located in the mitochondria. The N-terminal domain phosphorylation led 
to a decrease in glutaminase activity despite not being part of the glutaminase domain. Also 
present in the N-terminal domain, lysine 197 (K202 in mouse) has already been described as 
acetylated [45]. A recombinant purified K202E mutant, emulating acetylation, presented 
increased activity correlated with enhanced protein capacity to form more active double-
stranded fibers, through tetramer interaction via their N-terminal domain [22]. In addition, 
other post-translational modifications, such as succinylation (K164 [17]) and ubiquitinylation 
(K121 [19], K158 [18,19],  K164 [18]) were described in the glutaminase N-terminal domain, 
leading us to  speculate that this domain may be a glutaminase regulatory spot. 
GAC.S95D presented slightly decreased cell growth and cell migration-inducing 
properties compared to GAC.WT. Accordingly, the EMT marker vimentin, was diminished in 
cell expressing GAC.S95D.  Glutaminase participation in tumor cell migration and invasion is 
beginning to be elucidated [46]. TGF- -2-dependent 
GLS expression, glutamine metabolism and p53-related SNAIL expression that  impacts the 
EMT process [47]. GLS downregulation by shRNA decreased xenografic tumor growth of head 
and neck squamous cell carcinoma (HNSCC) [48]. In addition, glutaminase has been shown to 
play a role in cancer cell stemness in HNSCC [49]. Finally, in lung cancer, TGF- -induced 
EMT was related to an increased GAC isoform, followed by a decreased KGA [50]. In this 
regard, GAC appears to be important in cells malignancy. In summary our data shed light on 
GAC post-translational regulation in breast cancer cell, and, for the first time, characterized 
cellular S95 phosphorylation. Further research on how cells regulate the glutaminase 
phosphorylation, and how this is de-regulated in cancer, may reveal new insights for 
therapeutic approaches targeting this enzyme.  
5. Conclusion 
Glutamine metabolism addiction is related to one of the hallmarks of cell 
transformation: The deregulated energetics. The first step of glutaminolysis is the conversion 
of glutamine into glutamate, by the action of glutaminases. In this sense, glutaminases are of 
great importance for the tumorigenic process. The intracellular regulation of glutaminases 
activity by post-translation modifications is currently poorly characterized. In this study we 
have identified by mass spectrometry a phosphorylation in the GAC`s (one of the glutaminase 
isoforms) N-terminal domain. A phosphomimetic mutant S95D was generated and shown to 
have decreased glutaminase activity; cells expressing this mutant also presented diminished 
glutamine uptake, glutamate release and glutamate intracellular levels. Moreover, breast cancer 
cells expressing the S95D mutant presented decreased proliferation, migration, and 
protein levels. Taken together, phosphorylation of the serine residue 95 of the glutaminase C 
may have a regulatory role on this enzyme and impact breast cancer cell proliferation and 
migration. 
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Figures legends 
Figure 1  Mass spectrometry revealed that GAC is phosphorylated at its N-
terminal domain.  (a) Western blot of transfected GAC-V5 in the breast cancer cell line, 
BT549. WCL= whole cell lysate; FT= flow through; Beads = resin. (b) GAC-V5 
immunoprecipitation eluate from BT549 was digested with trypsin and analyzed by LC-
MS/MS. The spectrum corresponding to the peptide with a phosphorylated S95 residue 
(GSTHPGVpSPPAAPAAPGPK, m/z 667.65, +3) was manually validated for a, b and y ion 
series (identified in green, red and blue, respectively).  
Figure 2 - Compared to WT protein, the phosphomimetic mutant S95D presented 
decreased glutaminase activity in breast cancer cells. (a) Western blot of MDA-MB 
231 and BT549 stably expressing WT and mutated proteins confirming equal ectopic protein 
levels. (b) Immunofluorescence of BT549 expressing WT and mutant GAC showing 
mitochondrial localization. (c) Immunofluorescence quantification of BT549 expressing WT 
and S95D confirming even ectopic protein levels. (d) WCL glutaminase activity of BT549 and 
MDA-MB 231 expressing GAC.WT or GAC.S95D. (e) Western blot of immunoprecipitated 
(IP) GAC.WT and GAC.S95D from BT549, MDA-MB 231 and MDA-MB 436 revealed that 
equal amounts of protein were immunoprecipitated when using anti-V5 (GAC-V5 was not 
detected in the IgG control). (f) Glutaminase activity of these proteins. (g) MDA-MB 231 cells 
expressing GAC.S95D consume less glutamine and secrete less glutamate than cells expressing 
GAC.WT. (h) BT549 cells expressing GAC.S95D present lower glutamate level than cells 
expressing GAC.WT as assessed by a fluorescence resonance energy transfer assay (FRET). * 
 
Figure 3 - Ectopic expression of GAC.WT, but not GAC.S95D, increased cell 
migration and vimentin levels. (a) GAC.WT and GAC.S95D ectopic expression in MDA-
MB 231 increased cell proliferation compared to mock cells, although GAC.S95D has a smaller 
effect (compared to GAC.WT). (b) Wound healing assay revealed GAC.S95D had a decrease 
on cell migration compared to GAC.WT. Vimentin expression increased when GAC-V5 WT 
was expressed in MDA-MB-231 and BT549 while GAC.S95D shows similar levels observed 
in mock cells, as demonstrated by western blot (c) and immunofluorescence representative 
images (d) and staining quantification (e). 
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N-terminal phosphorylation of glutaminase C decreases its enzymatic activity and 
cancer cell migration 
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Supplementary figures legends
Figure S1-Mass spectrometry revealed that GAC is phosphorylated at its N-
terminal domain.  (a) Western blot of transfected GAC-V5 in the breast cancer cell 
line MDA-MB 436. WCL= whole cell lysate; FT= flow through; Beads= resin. (b) GAC-
V5 immunoprecipitation eluate from MDA-MB 436 was digested with trypsin and 
analyzed by LC-MS/MS. The spectrum corresponding to the peptide with a 
phosphorylated S95 residue (GSTHPGVpSPPAAPAAPGPK, m/z 667.65, +3) was 
manually validated for the a, b and y ion series (identified in green, red and blue, 
respectively).  
Figure S2 - Relative quantification of GAC mRNA levels. qPCR was performed 
using primers targeting the GAC-V5 construct or GAC itself. No statistically significant 
differences were found in the GAC.WT and GAC.S95D mRNA levels of stably 
transduced BT549 and MDA-MB 231 cells; GAC-V5.WT and GAC-V5.S95D 
expression levels were also deemed statistically equal in BT549. 
Figure S3  S95 phosphorylation did not affect mitochondrial redox 
homeostasis. The Mitosox probe was used to measure the mitochondrial superoxide 
level in cells. GAC.WT and GAC.S95D ectopic expression decreased superoxide levels, 
with no statistically significant differences between them. 
Supplementary tables titles 
S1 Table  Mass spectrometry data analysis of BT549 cells performed with 
MaxQuant. 
S2 Table  Mass spectrometry data analysis of MDA-MB-436 cells 
performed with MaxQuant. 
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